Ads
related to: new prostate cancer treatment drugs
Search results
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
Morningstar· 4 days agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate< ...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 3 days agoBiotech Stocks: A Groundbreaking Cancer Treatment Novartis won Food and Drug Administration approval...
Rakovina Therapeutics: AI a “paradigm shift” for cancer drug development
Proactive Investors· 4 days agoTherapeutics Inc (TSX-V:RKV), a Canadian biotechnology company focused on developing innovative...
Novartis raises forecasts as top drug sales beat Wall Street estimates
BioPharma Dive via Yahoo Finance· 5 days agoDemand for the former has grown following new treatment guidelines for heart failure, while...
PSA Detectable After Radical Prostatectomy
Medscape· 5 days agoFollowing radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoHyundai Bioscience announces its successful result from a preclinical study of a Niclosamide-based oral anticancer drug to treat triple-negative breast cancer< ...
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 5 days agoKey Recent Developments...therapy (TAT) programs. These targetedtreatments minimize damage to nearby...
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric...
WTVO - WQRF Rockford· 5 days agoNovartis today announced that the U.S. Food and Drug Administration (FDA) approved Lutathera® (lutetium Lu 177 dotatate) for the treatment of pediatric ...
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
Digital Journal· 1 day agoThis approach is innovative to developing new drug therapies that target DNA-damage response-related vulnerabilities that are common in many types of < ...
Novartis lifts guidance after Q1 results beat expectations
Reuters· 5 days ago, opens new tab on Tuesday raised its full-year guidance after reporting better-than-expected...
Ads
related to: new prostate cancer treatment drugs